SKIN
The “Medicalization Of Beauty”: Unpacking Skincare And Aesthetics' Convergence
The overlap between the beauty and aesthetics industries is increasing. L’Oréal recently took a 10% stake in Galderma, the pure-play dermatology company that markets Botox alternative Dysport, and Crown Laboratories announced it's acquiring Revance Therapeutics, the company behind Daxxify, another Botox alternative.
To make sense of these moves, for the latest edition
…
Rachel Brown·August 26, 2024·1 min read
The 30-second read
The overlap between the beauty and aesthetics industries is increasing. L’Oréal recently took a 10% stake in Galderma, the pure-play dermatology company that markets Botox alternative Dysport, and Crown Laboratories announced it’s acquiring Revance Therapeutics, the company behind Daxxify, another Botox alternative.
To make sense of these moves, for the latest edition of our ongoing series posing questions relevant to indie beauty, we asked 14 beauty investors, investment bankers and consultants the following: What can they tell us about the growing relationship between the beauty and aesthetics industries? Do you believe there will be more moves marrying these industries? If so, what could they look like?
The players
5 mentionedBrand
Galderma
Funding StatusPublic
Primary CategoryPharmaceutical
Brand
Crown Laboratories
Brand
AS Beauty
Founded2019
HQNew York, New York, United States
Revenue Range$150M+
Investor
T Investment
Founded2021
Investor
L'Oréal
TypeStrategic /Big Beauty (L'Oreal, Waldencast)
